The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Arsobal     [2-[4-[(4,6-diamino-1,3,5- triazin-2...

Synonyms: Specia, MELARSOPROL, Melarsoprolum, CHEMBL166, Mel B, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MELARSOPROL


Psychiatry related information on MELARSOPROL

  • The trypanosomicide action of melarsoprol led to a reduction in the number of sleep episodes, except in one patient whose health condition worsened during the third treatment session: sleep onset REM sleep phases (SOREMPs) decreased and the number of SWS episodes during a sleep episode increased [5].

High impact information on MELARSOPROL

  • Calcium also has a synergistic effect on melarsoprol, the only drug available for treating sleeping sickness patients with central nervous system involvement, and the concentration of calcium has been reported to be depressed inthe serum of experimentally infected animals [6].
  • 598 patients were evaluable: morbidity and death associated with melarsoprol-induced encephalopathy was reduced in patients who were given prednisolone [7].
  • Moreover, both As2O3 and melarsoprol comparably inhibited growth and induced apoptosis of PML+/+ and PML-/- MEFs, and inhibited colony-forming unit erythroid (CFU-E) and CFU granulocyte-monocyte formation in BM cultures of PML+/+ and PML-/- progenitors [4].
  • Melarsoprol was more potent than As2O3 at equimolar concentrations ranging from 10(-7) to 10(-5) mol/L [4].
  • Together, these results show that As2O3 and melarsoprol inhibit growth and induce apoptosis independent of both PML and PML-RARalpha expression in a variety of myeloid leukemia cell lines, and suggest that these agents may be more broadly used for treatment of leukemias other than APL [4].

Chemical compound and disease context of MELARSOPROL


Biological context of MELARSOPROL


Anatomical context of MELARSOPROL


Associations of MELARSOPROL with other chemical compounds


Gene context of MELARSOPROL


Analytical, diagnostic and therapeutic context of MELARSOPROL

  • The control group followed the 26-day standard Angolan schedule of three series of four daily injections of melarsoprol at doses increasing from 1.2 to 3.6 mg/kg within each series, with a 7-day interval between series [26].
  • RESULTS: The half-life of melarsoprol determined by HPLC was <1 hour compared with 35 hours determined by bioassay and atomic absorption spectroscopy, indicating the existence of active metabolites [18].
  • Of 65 T. b. gambiense isolates analyzed from a focus in north-western Uganda with high treatment failure rates following melarsoprol therapy, 38 had a mutated TbAT1 [25].
  • C3 levels increased after treatment with melarsoprol (Mel B) [27].
  • Further evaluation of the PCR method is required, in particular to determine whether PCR assays could be used in studies on patients who fail to respond to melarsoprol, as observed in several foci [28].


  1. Human African trypanosomiasis of the CNS: current issues and challenges. Kennedy, P.G. J. Clin. Invest. (2004) [Pubmed]
  2. Topical melarsoprol for trypanosomiasis. Jennings, F.W., Atouguia, J.M., Murray, M. Lancet (1993) [Pubmed]
  3. Options for field diagnosis of human african trypanosomiasis. Chappuis, F., Loutan, L., Simarro, P., Lejon, V., Büscher, P. Clin. Microbiol. Rev. (2005) [Pubmed]
  4. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Wang, Z.G., Rivi, R., Delva, L., König, A., Scheinberg, D.A., Gambacorti-Passerini, C., Gabrilove, J.L., Warrell, R.P., Pandolfi, P.P. Blood (1998) [Pubmed]
  5. Reversal of the sleep/wake cycle disorder of sleeping sickness after trypanosomicide treatment. Buguet, A., Tapie, P., Bert, J. Journal of sleep research. (1999) [Pubmed]
  6. Role of calcium in trypanocidal drug action. Clarkson, A.B., Amole, B.O. Science (1982) [Pubmed]
  7. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Pepin, J., Milord, F., Guern, C., Mpia, B., Ethier, L., Mansinsa, D. Lancet (1989) [Pubmed]
  8. Efficacy of combinations of difluoromethylornithine and bleomycin in a mouse model of central nervous system African trypanosomiasis. Clarkson, A.B., Bacchi, C.J., Mellow, G.H., Nathan, H.C., McCann, P.P., Sjoerdsma, A. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  9. A unique transporter of S-adenosylmethionine in African trypanosomes. Goldberg, B., Yarlett, N., Sufrin, J., Lloyd, D., Bacchi, C.J. FASEB J. (1997) [Pubmed]
  10. Drug treatment of tropical parasitic infections: recent achievements and developments. Stephenson, I., Wiselka, M. Drugs (2000) [Pubmed]
  11. Chemotherapy of human African trypanosomiasis. Burchmore, R.J., Ogbunude, P.O., Enanga, B., Barrett, M.P. Curr. Pharm. Des. (2002) [Pubmed]
  12. Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. Koshiuka, K., Elstner, E., Williamson, E., Said, J.W., Tada, Y., Koeffler, H.P. Br. J. Cancer (2000) [Pubmed]
  13. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. König, A., Wrazel, L., Warrell, R.P., Rivi, R., Pandolfi, P.P., Jakubowski, A., Gabrilove, J.L. Blood (1997) [Pubmed]
  14. Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Shahi, S.K., Krauth-Siegel, R.L., Clayton, C.E. Mol. Microbiol. (2002) [Pubmed]
  15. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. Pépin, J., Mpia, B. Emerging Infect. Dis. (2005) [Pubmed]
  16. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Soignet, S.L., Tong, W.P., Hirschfeld, S., Warrell, R.P. Cancer Chemother. Pharmacol. (1999) [Pubmed]
  17. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Rousselot, P., Labaume, S., Marolleau, J.P., Larghero, J., Noguera, M.H., Brouet, J.C., Fermand, J.P. Cancer Res. (1999) [Pubmed]
  18. Investigations of the metabolites of the trypanocidal drug melarsoprol. Keiser, J., Ericsson, O., Burri, C. Clin. Pharmacol. Ther. (2000) [Pubmed]
  19. Transverse myelitis due to trypanosomiasis in a middle aged Tanzanian man. Kibiki, G.S., Murphy, D.K. J. Neurol. Neurosurg. Psychiatr. (2006) [Pubmed]
  20. Molecular pharmacology of adenosine transport in Trypanosoma brucei: P1/P2 revisited. Geiser, F., Lüscher, A., de Koning, H.P., Seebeck, T., Mäser, P. Mol. Pharmacol. (2005) [Pubmed]
  21. Equivalence Trial of Melarsoprol and Nifurtimox Monotherapy and Combination Therapy for the Treatment of Second-Stage Trypanosoma brucei gambiense Sleeping Sickness. Bisser, S., N'siesi, F.X., Lejon, V., Preux, P.M., Van Nieuwenhove, S., Miaka Mia Bilenge, C., Buscher, P. J. Infect. Dis. (2007) [Pubmed]
  22. The melaminophenyl arsenicals melarsoprol and melarsen oxide interfere with thiamine metabolism in the fission yeast Schizosaccharomyces pombe. Schweingruber, M.E. Antimicrob. Agents Chemother. (2004) [Pubmed]
  23. RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Bajenova, O., Tang, B., Pearse, R., Feinman, R., Childs, B.H., Michaeli, J. Apoptosis (2004) [Pubmed]
  24. Effect of melarsoprol treatment on circulating IL-10 and TNF-alpha levels in human African trypanosomiasis. Rhind, S.G., Sabiston, B.H., Shek, P.N., Buguet, A., Muanga, G., Stanghellini, A., Dumas, M., Radomski, M.W. Clin. Immunol. Immunopathol. (1997) [Pubmed]
  25. Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Matovu, E., Geiser, F., Schneider, V., Mäser, P., Enyaru, J.C., Kaminsky, R., Gallati, S., Seebeck, T. Mol. Biochem. Parasitol. (2001) [Pubmed]
  26. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Burri, C., Nkunku, S., Merolle, A., Smith, T., Blum, J., Brun, R. Lancet (2000) [Pubmed]
  27. Complement activation in patients with Gambian sleeping sickness. Greenwood, B.M., Whittle, H.C. Clin. Exp. Immunol. (1976) [Pubmed]
  28. Use of polymerase chain reaction in human African trypanosomiasis stage determination and follow-up. Truc, P., Jamonneau, V., Cuny, G., Frézil, J.L. Bull. World Health Organ. (1999) [Pubmed]
WikiGenes - Universities